reviewNeuropharmacologyOct 6, 2020HYBRID OA

Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

Università di Camerino

PubMed
Indexed incrossrefpubmed

Abstract

Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations. The main class of drugs currently used for the treatment of AD are acetylcholinesterase/cholinesterase inhibitors (ChE-Is). The first ChE-I licensed for symptomatic treatment of AD was tacrine. The ChE-Is currently available in the market are donepezil, rivastigmine and galantamine as tacrine is no longer in use, due to its hepatotoxicity. According to mechanism of action the ChE-Is are classified as short-acting or reversible agents such as tacrine, donepezil, and galantamine, as intermediate-acting or pseudo-irreversible agent such…

Citation impact

1,055
total citations
FWCI
61.37
Percentile
100%
References
156
Citations per year

Authors

6

Topics & keywords

Keywords
  • Tacrine
  • Donepezil
  • Galantamine
  • Rivastigmine
  • Acetylcholinesterase
  • Pharmacology
  • Cholinesterase
  • Memantine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding